Barinthus Bio Phase 1 AVALON trial of VTP-1000 shows safety, dose-dependent effect in celiac disease

Barinthus Biotherapeutics plc.

VTP-1000 well-tolerated in SAD portion; no treatment-related serious adverse events.
Dose-dependent pharmacological effect observed across 18 patients in three cohorts.
MAD portion with gluten challenge ongoing; data expected in second half of 2026.
VTP-1000 uses SNAP-TI platform to co-deliver gluten antigens and rapamycin, promoting immune tolerance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.